• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24897 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     NIHR Health Technology Assessment programme The work and vocational advice intervention for adults in full or part-time employment: a synopsis of the WAVE feasibility study and RCT
2026     NIHR Health Technology Assessment programme BEhavioural Weight Management: COMponents of Effectiveness (BE:COME) Synopsis
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Art therapy: visual arts in the management of mild cognitive impairment]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Hugging for pain, depression and anxiety relief]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, clinical effectiveness and cost-effectiveness of neonatal screening for Pompe disease]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, clinical and cost-effectiveness of neonatal screening for type 1 citrullinaemia, trifunctional protein deficiency, holocarboxyl synthetase deficiency, argininosuccinic aciduria and 3-methylcrotonyl-CoA carboxylase deficiency]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Telemedicine for the follow-up of post-stroke patients]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Artificial intelligence software to detect viable tissue in stroke patients on CT or perfusion MRI of the skull]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Neurosurgical robot for electrode implantation, brain biopsies and spinal surgery]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of model-informed precision dosing of biologic agents]
2026     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of modifications to the BreastCheck programme. Workstream 1 (of 2): consideration of screening pathways that incorporate breast density
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of pelvic floor training during pregnancy for the prevention of pre and postnatal urinary incontinence]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Laboratory animals – farm animals: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Flour: Evidence report for the S3 guideline on allergic rhinitis]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pets-rodents: Evidence report for the S3 guideline on allergic rhinitis]
2026     NIHR Health Services and Delivery Research programme Implementing artificial intelligence in chest diagnostics for lung disease: a mixed-methods evaluation
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pollen: Evidence report for the S3 guideline on allergic rhinitis]
2026     NIHR Health Technology Assessment programme Diagnostic tools to establish the presence and severity of peripheral arterial disease in people with diabetes: a synopsis of the DM PAD prospective multicentre diagnostic accuracy study
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [House dust mites: Evidence report for the S3 guideline on allergic rhinitis]
2026     Health Information and Quality Authority (HIQA) Scalable training and knowledge exchange on guideline development for patients, public, and healthcare professionals (The STAKEholder Project)
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Test quality: Evidence report for the S3 guideline on allergic rhinitis]
2026     NIHR Health Technology Assessment programme Relative and bedside nurse assessment of comfort and communication during propofol, dexmedetomidine, or clonidine-based sedation: pre-planned analysis within the A2B RCT
2026     NIHR Health Technology Assessment programme Understanding barriers and facilitators of implementing a new assessment and bridging tool to support those at risk of repeat self-harm in prison: the qualitative RAPPS study
2026     NIHR Health Technology Assessment programme Validating and updating the OHTS-EGPS model predicting 5-year glaucoma risk among patients with ocular hypertension using electronic medical records: a cohort study
2026     NIHR Health Services and Delivery Research programme A randomised feasibility trial of an intervention involving mental health support workers as link workers to improve dental visiting in people with severe mental illness: The Mouth Matters in Mental Health Study
2026     NIHR Health Services and Delivery Research programme The use of restrictive practices in the everyday care of people living with dementia in hospital settings: an ethnographic study
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Chronic obstructive pulmonary disease (COPD)]
2026     NIHR Health Technology Assessment programme Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Local hyperbaric oxygen therapy for diabetic foot ulcers]
2026     NIHR Health Technology Assessment programme Timing of birth to improve outcomes in chronic or gestational hypertension: the WILL RCT
2026     HTA South [Biomarkers as support in decision-making for computed tomography in mild head injury in adults – a systematic review and assessment of medical, economical and ethical aspects]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fundus photography for the diagnosis of diabetic retinopathy]
2026     NIHR Health Technology Assessment programme Reducing self-harm in adolescents: the RISA-IPD comprehensive synopsis
2026     NIHR Health Technology Assessment programme Home-based extended rehabilitation for older people with frailty (HERO): a multicentre randomised controlled trial with health economic analysis and process evaluation
2026     NIHR Health Services and Delivery Research programme Models of perinatal care for women using drugs and their infants: synopsis of The Stepping Stones Study
2026     NIHR Health Services and Delivery Research programme Intervening to eliminate the centre-effect variation in home dialysis use: a synopsis of Inter-CEPt, an exploratory sequential mixed-methods study
2026     NIHR Health Technology Assessment programme Clinical utility of biomarkers for outcomes prediction in adults with suspected sepsis presenting to the emergency department: a synthesis of current evidence
2026     NIHR Health Technology Assessment programme Effectiveness and cost-effectiveness of targeted and population screening for osteoporosis in women: scoping review
2026     NIHR Health Technology Assessment programme Interventions to safely and effectively reduce (taper) use of opioids in chronic non-cancer pain: a systematic review
2026     NIHR Health Technology Assessment programme Comparing the clinical and cost-effectiveness of various washout policies in preventing catheter associated complications in adults living with long-term catheters: synopsis of the CATHETER II RCT
2026     Scottish Health Technologies Group (SHTG) Surface guided radiation therapy (SGRT)
2026     National Institute for Health and Care Excellence (NICE) Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause. NICE technology appraisal guidance 1143
2026     National Institute for Health and Care Excellence (NICE) Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils. NICE technology appraisal guidance 1142
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radiofrequency energy treatment for organic erectile dysfunction]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Economic evaluation of a booster dose of Tdap vaccine in adolescents]
2026     National Institute for Health and Care Excellence (NICE) Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over. NICE technology appraisal guidance 1140
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety, clinical effectiveness, and cost-effectiveness of neonatal screening for beta-ketothiolase deficiency and classic galactosemia. Update]
2026     National Institute for Health and Care Excellence (NICE) Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal). NICE technology appraisal guidance 1141
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Exercise programs for cancer patients over 65 years of age undergoing chemotherapy. Systematic review]
2026     National Institute for Health and Care Excellence (NICE) Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment. NICE technology appraisal guidance 1139
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of endovascular treatment using transarterial radioembolization for intermediate and advanced hepatocellular carcinoma]
2026     National Institute for Health and Care Excellence (NICE) Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer. NICE technology appraisal guidance 1138
2026     National Institute for Health and Care Excellence (NICE) Pegzilarginase for treating arginase-1 deficiency in people 2 years and over. NICE highly specialised technologies guidance 35
2026     National Institute for Health and Care Excellence (NICE) Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock. NICE HealthTech guidance 774
2026     National Institute for Health and Care Excellence (NICE) Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock. NICE HealthTech guidance 775
2026     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI) technologies to help detect or characterise colorectal polyps. NICE HealthTech guidance 773
2026     NIHR Health Technology Assessment programme Methods and mechanisms for measuring and monitoring outcomes from newborn bloodspot screening: a scoping review
2026     National Institute for Health and Care Excellence (NICE) Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation. NICE HealthTech guidance 772
2026     Scottish Health Technologies Group (SHTG) Wearable home-testing devices for diagnosing obstructive sleep apnoea syndrome (OSAHS)
2026     Scottish Health Technologies Group (SHTG) Out-of-hospital cardiac arrest (OHCA)
2026     Scottish Health Technologies Group (SHTG) Robotic assisted bronchoscopy (RAB)
2026     Scottish Health Technologies Group (SHTG) Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (OSAHS)
2026     Scottish Health Technologies Group (SHTG) Computed tomography fractional flow rate (CT-FFR)
2026     Scottish Health Technologies Group (SHTG) Specialist interventions for managing chronic non-malignant pain in adults
2026     Scottish Health Technologies Group (SHTG) Surgical care practitioners
2026     NIHR Health Services and Delivery Research programme Referral pathways into the NHS Digital Weight Management Programme for musculoskeletal and perioperative patients: rapid process evaluation
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for prostate cancer]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of the regulations governing a tiered system of emergency structures in hospitals]
2026     NIHR Health Technology Assessment programme Addition of early vocational advice to usual primary care on sickness absence in employed adults: exploratory findings from the discontinued WAVE Randomised Controlled Trial
2026     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of medical management versus surgery for deep infiltrating endometriosis: synopsis from the DIAMOND RCT
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Immunological assays of tacrolimus and cyclosporine]
2026     National Institute for Health and Care Excellence (NICE) Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy. NICE technology appraisal guidance 1126
2026     NIHR Health Services and Delivery Research programme Independence and interdependence of non-medical practitioners in the emergency care skill-mix (SKILLMix-ED): a multi-method study to develop a measurement tool
2026     National Institute for Health and Care Excellence (NICE) Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal). NICE technology appraisal guidance 1124
2026     NIHR Health Services and Delivery Research programme Accounting for needs in geographical health care resource allocation
2026     National Institute for Health and Care Excellence (NICE) Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal). NICE technology appraisal guidance 1125
2026     NIHR Health Services and Delivery Research programme Lifeguard Pharmacy - A feasibility trial of a novel pharmacy-based intervention for people experiencing domestic abuse and/or suicidal ideation
2026     National Institute for Health and Care Excellence (NICE) Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal). NICE technology appraisal guidance 1123
2026     NIHR Health Technology Assessment programme Development and description of Early Stroke Specialist Vocational Rehabilitation delivered in the RETAKE trial
2026     National Institute for Health and Care Excellence (NICE) Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1122
2026     National Institute for Health and Care Excellence (NICE) Acoramidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 1121
2026     NIHR Health Services and Delivery Research programme Evidence base to inform health service configuration for abortion provision: the SACHA (Shaping Abortion for Change) multi-component study
2026     National Institute for Health and Care Excellence (NICE) Avelumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 1120
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Sentinel injuries: suggestive signs of inflicted injuries in precruising infants]
2026     National Institute for Health and Care Excellence (NICE) Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 1118
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment algorithm for acute lymphoblastic leukemia in adults]
2026     National Institute for Health and Care Excellence (NICE) Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 1119
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Tumor biomarkers related to the management of advanced thyroid cancer]
2026     National Institute for Health and Care Excellence (NICE) Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessment. NICE HealthTech guidance 766
2026     National Institute for Health and Care Excellence (NICE) Digital self-help for eating disorders: early value assessment. NICE HealthTech guidance 768
2026     Swiss Federal Office of Public Health (FOPH) Ginkgo biloba in patients with decreasing mental performance, peripheral arterial occlusive disease, vertigo or tinnitus
2026     Swiss Federal Office of Public Health (FOPH) Valerian extracts for sleep disorders, anxiety or restlessness
2027     Health Information and Quality Authority (HIQA) Health Technology Assessment (HTA) of the transition to, and coordination of, adult healthcare services for individuals with severe neurological impairment
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Short frenulum in infants: what are the advantages and disadvantages of frenectomy (cutting the frenulum) compared to, for example, breastfeeding counseling for breastfeeding problems?]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anxiety and panic disorder: do those affected benefit from the "emotional freedom technique”?]
2027     Belgian Health Care Knowledge Centre (KCE) Review of new oncology indications for the use of positron emission tomography (PET-scans) (Study 2024-12)
2027     Norwegian Medical Products Agency (NOMA) [Wearable cardioverter defibrillator (LifeVest) for people with high risk of sudden cardiac arrest: a single technology assessment]